Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study

Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib (ABL001) vs. bosutinib.